AIMS: The results of 52 endoresections for @entity320 are reported. METHODS: The current technique involves vitrectomy, retinal incision over or peripheral to the @entity5 , haemostasis by raising intraocular pressure and by moderate @entity551 anaesthesia, choroidal incision around @entity5 , endoresection with vitrector, endodiathermy to @entity548 points and @entity5 , fluid-air exchange to reattach retina, endolaser to achieve retinal adhesion around the @entity4643 and @entity5 in the sclera, silicone oil injection with removal after 12 weeks, cryotherapy to the sclerotomies, and adjunctive @entity3739 plaque radiotherapy in selected cases. RESULTS: @entity1 receiving primary endoresection had a mean age of 53 years, a mean largest basal @entity5 diameter of 8.2 mm, and a mean @entity5 thickness of 3.9 mm. 40 @entity5 extended to within 2 disc diameters of the optic disc, with 17 involving disc. Follow up ranged from 40 days to 7 years (median 20 months). At the last visit, 90% of eyes were retained, with vision of 6/6-6/12 (two), 6/18-6/36 (three), 6/60 to counting fingers (18), hand movements (nine), and light perception (four). The main complications were @entity1713 in 16 and @entity231 in 25. Secondary endoresection (11) was performed after plaque radiotherapy (four), photocoagulation (four), trans-scleral local resection (two), and proton beam radiotherapy (one), with retention of the eye in nine cases. By the close of the study, no @entity1 developed @entity5 recurrence but one died of metastatic disease 41 months postoperatively. CONCLUSION: Depending on @entity5 location, endoresection may conserve central vision or temporal field when radiotherapy would be expected to cause @entity1781 . Longer follow up is necessary to establish the efficacy of @entity5 control.

Endoresection of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity5 :: ('MESH:D009369', 'Disease') :: ['residual tumour', 'destroy residual tumour', 'definite local tumour', 'tumours', 'tumour'] @entity1713 :: ('MESH:D012163', 'Disease') :: ['retinal detachment'] @entity3739 :: ('MESH:D012428', 'Chemical') :: ['ruthenium'] @entity1781 :: ('MESH:D009901', 'Disease') :: ['optic neuropathy'] @entity4643 :: ('MESH:D003103', 'Disease') :: ['coloboma'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive'] @entity320 :: ('MESH:D008545', 'Disease') :: ['choroidal melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['choroidal melanoma']
